11月17日 - ** 制药商爵士制药JAZZ.O股价盘前上涨13.4%至160美元
** 公司称其药物Ziihera与化疗相结合，在治疗一种胃癌的晚期研究中达到了主要目标
** 在这项研究中，Ziihera与标准疗法联合化疗相比，患者的无进展生存期和总生存期都有了有意义的、统计学意义上的显著改善 - JAZZ
** JAZZ与Zymeworks ZYME.O共享治疗权，后者的股价盘前也上涨了43.52%。
** 公司计划于2026年上半年向美国FDA提交该适应症的上市申请
** Ziihera 已在美国获得 (link) 批准，用于治疗一种胆道癌。
** 截至上次收盘，JAZZ上涨14.6%，ZYME上涨26.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.